Covid-19: Malaysia continues four-digit streak with 1,196 new confirmed cases, active cases remain above 20,000-mark
Malaysia's current hospital beds occupancy rate to treat Covid-19 patients may already stand at approximately 80%.
Malaysia's current hospital beds occupancy rate to treat Covid-19 patients may already stand at approximately 80%.
Pushing the country's cumulative total cases to 103,900.
Health director-general Tan Sri Dr Noor Hisham Abdullah: So we will try our best to carry out the processes that have been identified so that we can reduce the time for us to conditionally register the vaccine within a period of less than 90 days.
The vote ended with 111 MPs in favour and 108 MPs against the passing of the budget. One MP was absent out of the 220 members. The 111 votes represent a simple majority.
JHM said the acquisition of the land is to enable the company to expand its business into telecommunication equipment manufacturing industries that serve multiple multinational corporations in North American, Europe and Asia, tapping into the growing demand for Internet of Things application, as well as Cloud/Data Center.
AEON BiG (M) Sdn Bhd, in a statement today, said the appeals court dismissed landlord Mega Continental Sdn Bhd’s appeal against the November 2019 judgment of the High Court in Penang.
His Majesty pointed out that it will be recorded in history as a reflection of failure of state leadership rather than a success.
Khairy also rejected Razaleigh’s claim that Putrajaya has used up the entire allocation of RM3 billion to cover just 20% of the population.
Minister of Science, Technology and Innovation Khairy Jamaluddin: I would like to inform market investors in Malaysia that the announcements [by private companies related to Covid-19 vaccines] do not mean that they are procured by the government. So far, the only procurement made by the government is with COVAX for 10% of the population, and Pfizer for 20% of the population. These arrangements are made directly by the government without the use of any middleman or third party
Yong Tai will be SZKT's partner in Malaysia to conduct Phase III clinical trials and exclusive commercialisation of the vaccine.